- NCIt
- C5028
Loading cancer entity…
Loading cancer entity…
Clinical trials
110 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07806617 | Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts | active not recruiting | Phase 2 | 55 | Rush University Medical CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07698886 | Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel | recruiting | Phase 2 | 70 | KTH BiopharmaINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07637734 |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)(COVE-3) |
| recruiting |
| Phase 3 |
| 300 |
| Verrica Pharmaceuticals Inc.INDUSTRY |
| 2 |
| Sep 3, 2026 |
| clinicaltrials |
| NCT03977753 | Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts(EVAsION) | recruiting | Phase 4 | 162 | Labo'LifeINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07448844 | Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir | recruiting | Phase 4 | 40 | Riphah International UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT04635423 | Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064) | completed | Phase 3 | 1,059 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07457918 | Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)(COVE-4) | recruiting | Phase 3 | 600 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07543926 | New Treatment of Common Wart | not yet recruiting | N/A | 70 | Sohag UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05937672 | Cold Atmospheric Plasma Device Extension Study | terminated | Phase 3 | 60 | Medical University of South CarolinaOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02773719 | Biofields Therapy on Warts(MAGNETIK) | completed | N/A | 62 | University Hospital, CaenOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02750202 | Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts(TheraVACCS) | completed | Phase 3 | 52 | University of PretoriaOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07246590 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)(COVE-2) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06756269 | To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years | recruiting | Phase 2 | 330 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05087849 | Intralesional HPV Vaccine for Condylomata | completed | Phase 1 / Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05889845 | Candin for the Treatment of Common Warts | completed | Phase 3 | 330 | Nielsen BioSciences, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT00092534 | Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)(FUTURE II) | completed | Phase 3 | 12,167 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2025 | clinicaltrials |
| NCT06866574 | A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males | active not recruiting | Phase 3 | 9,300 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05799157 | Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | completed | Phase 2 | 153 | Veradermics, Inc.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06915779 | Long Term Follow-up of HPV Vaccine in HIV (CTN 236) | completed | — | 241 | University of British ColumbiaOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06214559 | Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts. | completed | N/A | 33 | Swiss Footcare Laboratories - Poderm ProfessionalINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT05100043 | Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts | completed | — | 80 | Zagazig UniversityOTHER_GOV | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06454175 | A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years | unknown | Phase 1 | 72 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06749665 | Sclerotherapy and Candida Antigen in Treatment of Common Warts | not yet recruiting | N/A | 75 | Sohag UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03487549 | Cantharidin and Occlusion in Verruca Epithelium(COVE-1) | completed | Phase 2 | 56 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06700941 | Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment | completed | — | 8,000,000 | Universidad Nacional de ColombiaOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02653118 | Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) | active not recruiting | — | 4,453 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
| NCT05896215 | OM202JP Clinical Study of KNP2002 | completed | Phase 2 | 159 | KinoPharma Inc.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04422366 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | recruiting | Phase 3 | 8,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT04895020 | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | unknown | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05027776 | Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years | recruiting | Phase 3 | 1,348 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05371353 | Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | recruiting | — | 600 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05518201 | Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05877313 | Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) | completed | Phase 2 | 20 | Sanotize Research and Development corp.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05070754 | Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca | completed | Phase 4 | 17 | Medical University of South CarolinaOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04738734 | CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts | completed | N/A | 150 | Pulse Biosciences, Inc.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01796795 | Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients | suspended | Phase 2 | 102 | G&E Herbal Biotechnology Co., LTDINDUSTRY | 0 | Sep 14, 2023 | clinicaltrials |
| NCT04554394 | CellFX System for the Treatment of Cutaneous Non-Genital Warts | completed | N/A | 62 | Pulse Biosciences, Inc.INDUSTRY | 1 | Jul 27, 2023 | clinicaltrials |
| NCT04793529 | Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study | completed | N/A | 60 | Benha UniversityOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | terminated | Phase 3 | 3,131 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT04823845 | Plantar Wart Treatment Using Adapalene Gel | withdrawn | Early Phase 1 | 0 | University of LouisvilleOTHER | 0 | Apr 13, 2023 | clinicaltrials |
| NCT02462187 | Topical NVN1000 for the Treatment of External Genital and Perianal Warts | completed | Phase 2 | 108 | Novan, Inc.INDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05115669 | Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts | completed | N/A | 50 | Karo Pharma ABINDUSTRY | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05314023 | Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) | active not recruiting | Phase 3 | 1,590 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jan 19, 2023 | clinicaltrials |
| NCT01746056 | A Comparative Study of Occlusive Heat Patch in the Treatment of Warts | completed | N/A | 73 | Yale UniversityOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05488860 | Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases | unknown | N/A | 20 | Xiangya Hospital of Central South UniversityOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05409365 | Assessment of Squamous Cell Carcinoma antigen2 in Verruca Vulgaris | unknown | — | 50 | Sohag UniversityOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT02759900 | Using a Cold Atmospheric Plasma Device to Treat Skin Disorders | unknown | N/A | 100 | The Skin Center Dermatology GroupINDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials